GUT microbiome and regulation on immune responses in guillain-barre syndrome: a prospective controlled study
Ended Project Grant Awarded Last action
- Award ID
- R21TW012184
- Recipient
-
International Centre For Diarrhoeal Disease Research, Bangladesh UEI MS5NE1JLU463
- Awarding agency
-
Fogarty International Center
National Institutes of Health, Department of Health and Human Services
- Obligated
- $807,837
Award facts
- Assistance listing
- 93.989 International Research and Research Training
- Completion date
- Originally
- Funding
-
- $538,558.00 Federal
- $269,279.00 Non-federal
- Place of performance
- Bangladesh
Award details come from USAspending.gov.
Description
- Abstract
- Guillain-barre syndrome (GBS) has become a major health burden in low- and middle-income countries (LMIC) after post-polio ERA. The prognosis of GBS has not improved over the last two decades. Our group previously showed that the incidence, disease severity and mortality of GBS are higher in BANGLADESH compared to the developed world. Little is known about the factors that influence disease pathogenesis and severity in patients with GBS in LMIC. We aim to identify the firmicutes rich species in GUT microbiome in patients with GBS and determine the regulation of T and B cell responses imposed by the host microbiome. The main hypothesis of the current project is whether GUT microbiome plays a vital role in regulation of the cellular immune response during the pathogenesis of GBS. Our specific aims will test the following hypotheses: specific aim #1: we will identify and compare species from the firmicutes phylum in the GUT microbiome of patients with GBS versus uncomplicated campylobacter jejuni enteritis controls and correlate between GUT microbial involvement and disease severity in patients with GBS. Specific aim #2: we will determine GUT microbiome regulation of T and B cell differentiation to predict immune tolerance during disease progression and identify the association with the severity of GBS. The current project is the very first attempt taken from LMIC to find the host GUT microbiome factors of GBS patients. This study will be a collaborative initiative between upper and middle in-come countries (UMICS) and lmics to explore the pathogenesis of such a long term neurological disorder. The aims proposed in this exploratory/developmental grant application is built upon ongoing, long-standing collaborative efforts between the icddr, B (BANGLADESH), erasmus MC, university medical centre (rotterdam, the netherlands), the university of california (davis, USA), johns hopkins university (baltimore, USA) and the national institute of neurosciences & hospital (dhaka, BANGLADESH). This exploratory study will be the road map to understand the GUT microbiome regulation in immune-pathogenesis of GBS and identify potential therapeutic targets in future.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $135,000 | $0 | |
| Amendment | $135,000 | $135,000 | |
| Amendment | $134,279 | $0 | |
| Original award | $134,279 | $134,279 |
Quick answers
Who received award R21TW012184?
R21TW012184 was awarded to International Centre For Diarrhoeal Disease Research, Bangladesh by Fogarty International Center (National Institutes of Health) on September 15, 2021.
How much is award R21TW012184 worth?
$807,837 has been obligated on R21TW012184: $538,558 in federal funding and $269,279 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award